Outsourcing BA/BE studies MCQs With Answer

Outsourcing BA/BE studies MCQs With Answer is designed to help M. Pharm students master the regulatory, scientific, and operational nuances of outsourcing bioavailability/bioequivalence programs. From selecting and qualifying CROs to understanding global guidelines (FDA, EMA, ICH) and national regulations, this quiz covers end-to-end considerations such as study design, subject safety, data integrity, contracts, bioanalytical validation, and submission readiness. Each question focuses on real-world decision points: vendor oversight, quality agreements, Part 11 compliance, ISR, RSABE, NTI drugs, and more. Use these MCQs to sharpen your regulatory affairs perspective, improve audit/inspection readiness, and gain confidence in planning and supervising outsourced BA/BE studies that are scientifically sound and fully compliant.

Q1. In outsourcing BA/BE studies, what is the most compelling advantage for sponsors seeking quality and speed?

• Eliminating sponsor regulatory responsibility
• Access to specialized expertise and validated infrastructure
• Avoiding ethics committee approval
• Skipping bioanalytical method validation

Correct Answer: Access to specialized expertise and validated infrastructure

Q2. Which guidance clearly states that a sponsor may transfer trial-related duties to a CRO but retains overall responsibility?

• ICH Q7
• ICH E6 (R2) Good Clinical Practice
• OECD GLP Principles
• USP <905>

Correct Answer: ICH E6 (R2) Good Clinical Practice

Q3. In the U.S., which regulation specifically addresses bioavailability and bioequivalence requirements?

• 21 CFR Part 11
• 21 CFR Part 312
• 21 CFR Part 320
• 21 CFR Part 210

Correct Answer: 21 CFR Part 320

Q4. When a CRO uses electronic data capture and LC-MS/MS systems, which regulation ensures compliant electronic records and signatures?

• 21 CFR Part 11
• ICH Q3C
• EMA Module 1
• USP <1225>

Correct Answer: 21 CFR Part 11

Q5. For immediate-release oral formulations, which study design is most commonly used to establish BE?

• Parallel-group single-period design
• Two-period, two-sequence crossover (2×2)
• Factorial design
• N-of-1 trial

Correct Answer: Two-period, two-sequence crossover (2×2)

Q6. For highly variable drugs, which statistical approach may be used to justify widened Cmax limits under certain regulators?

• Population bioequivalence without replication
• Reference-scaled average bioequivalence (RSABE)
• Nonparametric ANOVA
• Super-bioavailability testing

Correct Answer: Reference-scaled average bioequivalence (RSABE)

Q7. Which PK metrics are typically used to decide bioequivalence for most immediate-release products?

• Ctrough and AUCtau with 95% CI within 70.00–143.00%
• Cmax and AUC with 90% CI within 80.00–125.00%
• Tmax only with nonparametric test
• Kel and t½ with 90% CI within 90.00–110.00%

Correct Answer: Cmax and AUC with 90% CI within 80.00–125.00%

Q8. Which contract document best defines scope, deliverables, timelines, and responsibilities for an outsourced BA/BE project?

• Master Service Agreement (MSA)
• Quality Agreement
• Statement of Work (SOW)
• Change Control Form

Correct Answer: Statement of Work (SOW)

Q9. What is the primary purpose of a pre-award site qualification audit of a CRO/clinical unit for BA/BE?

• To negotiate the lowest per-subject cost
• To evaluate compliance systems, capabilities, and capacity
• To finalize the clinical trial insurance certificate
• To confirm the marketing authorization holder

Correct Answer: To evaluate compliance systems, capabilities, and capacity

Q10. Which activity verifies the reproducibility of bioanalytical results using actual study samples?

• Calibration curve evaluation
• Dilution integrity
• Incurred Sample Reanalysis (ISR)
• Carryover assessment

Correct Answer: Incurred Sample Reanalysis (ISR)

Q11. For most drugs, what is the standard regulatory acceptance interval for the 90% CI of Test/Reference geometric mean ratios?

• 75.00–133.00%
• 80.00–125.00%
• 70.00–143.00%
• 90.00–110.00%

Correct Answer: 80.00–125.00%

Q12. For narrow therapeutic index (NTI) drugs in BE studies, which statement is generally true?

• Wider acceptance limits are usually allowed
• Tighter acceptance limits and additional metrics may be required
• Only Tmax needs to be matched
• Parallel design is mandatory

Correct Answer: Tighter acceptance limits and additional metrics may be required

Q13. In India, the conduct and approval of BA/BE studies are currently governed primarily by which rules?

• Schedule M of Drugs and Cosmetics Rules
• Schedule Y (superseded framework)
• New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019)
• Medical Devices Rules, 2017

Correct Answer: New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019)

Q14. Before sharing a protocol and proprietary data with a potential CRO, which agreement is typically executed?

• Purchase Order
• Confidentiality/Non-Disclosure Agreement (CDA/NDA)
• Financial Disclosure Form
• Insurance Binder

Correct Answer: Confidentiality/Non-Disclosure Agreement (CDA/NDA)

Q15. Which approach best supports sponsor oversight of an outsourced BA/BE study?

• Delegating all monitoring to the CRO with no sponsor review
• A documented vendor oversight plan with KPIs and governance meetings
• Auditing only after database lock
• Relying solely on CRO marketing materials

Correct Answer: A documented vendor oversight plan with KPIs and governance meetings

Q16. In a 2×2 crossover BE study, which factor most strongly drives sample size requirements?

• Inter-subject variability only
• Intra-subject variability (CV%) of key PK parameters
• Number of analytical batches
• Washout duration

Correct Answer: Intra-subject variability (CV%) of key PK parameters

Q17. Regarding informed consent in BA/BE studies, which is correct?

• The sponsor obtains consent after dosing
• The investigator obtains consent only before randomization
• The investigator must obtain consent before any study-specific procedures
• The CRO project manager documents consent on behalf of the investigator

Correct Answer: The investigator must obtain consent before any study-specific procedures

Q18. If a bioanalytical run fails predefined acceptance criteria, what is the appropriate action?

• Report results as is and note a deviation
• Exclude failing QCs and keep the rest
• Investigate, document root cause, and repeat the run per SOP and acceptance criteria
• Adjust calibration curve post hoc to force acceptance

Correct Answer: Investigate, document root cause, and repeat the run per SOP and acceptance criteria

Q19. In data integrity, ALCOA refers to which set of principles?

• Available, Logical, Consistent, Objective, Auditable
• Attributable, Legible, Contemporaneous, Original, Accurate
• Assured, Legal, Controlled, Organized, Archived
• Accessible, Licensed, Certified, Operational, Authorized

Correct Answer: Attributable, Legible, Contemporaneous, Original, Accurate

Q20. For FDA submissions, which forms disclose clinical investigator financial interests in BA/BE studies?

• Form FDA 1572
• Form FDA 356h
• Forms FDA 3454/3455
• FDA 483

Correct Answer: Forms FDA 3454/3455

Download